Some analysts estimate that more than 100 incretin-modulating candidates, across GLP-1, GIP, glucagon, amylin, and novel multi-agonist combinations, are now in development. Over 50 companies are vying for a slice of this opportunity, from biotechnology newcomers to multinational giants. …
Pfizer’s high-stakes sprint to build momentum in century-defining market
December 11, 2025 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
Medicines Australia gains a new voice with Vertex joining the association
December 11, 2025 - - Latest News -
BMS marks 70 years in Australia with renewed commitment to innovation and access
December 11, 2025 - - Latest News -
Opportunity cost is a moral and ethical question when it involves travel, tickets, or treating sick children
December 11, 2025 - - Latest News -
Pfizer’s high-stakes sprint to build momentum in century-defining market
December 11, 2025 - - Latest News -
Mayne Pharma rejects Cosette’s attempt to terminate scheme deal
December 10, 2025 - - Latest News -
TGA clears the way for LTR Pharma’s Phase 2 Study of SPONTAN
December 10, 2025 - - Australian Biotech -
OncoSil announces first UK patient treated with its pancreatic cancer treatment
December 10, 2025 - - Australian Biotech